Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
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
YYrjRZRWaUJq96b6